AngioDynamics (ANGO) Projected to Post Quarterly Earnings on Tuesday

AngioDynamics (NASDAQ:ANGO) is projected to release its Q2 2026 results before the market opens on Tuesday, January 6th. Analysts expect AngioDynamics to post earnings of ($0.10) per share and revenue of $76.4330 million for the quarter. Individuals can find conference call details on the company’s upcoming Q2 2026 earning report page for the latest details on the call scheduled for Tuesday, January 6, 2026 at 8:00 AM ET.

AngioDynamics (NASDAQ:ANGO) last posted its quarterly earnings data on Thursday, October 2nd. The medical instruments supplier reported ($0.10) EPS for the quarter, topping the consensus estimate of ($0.12) by $0.02. AngioDynamics had a negative net margin of 10.67% and a negative return on equity of 3.16%. The business had revenue of $75.71 million for the quarter, compared to analyst estimates of $72.69 million. During the same quarter in the previous year, the firm posted ($0.11) earnings per share. AngioDynamics’s quarterly revenue was up 12.1% on a year-over-year basis. On average, analysts expect AngioDynamics to post $0 EPS for the current fiscal year and $0 EPS for the next fiscal year.

AngioDynamics Stock Performance

Shares of NASDAQ ANGO opened at $12.68 on Monday. The company has a 50 day simple moving average of $12.67 and a two-hundred day simple moving average of $10.98. AngioDynamics has a fifty-two week low of $8.27 and a fifty-two week high of $13.99. The company has a market capitalization of $522.42 million, a price-to-earnings ratio of -16.26 and a beta of 0.47.

Insider Transactions at AngioDynamics

In related news, CEO James C. Clemmer acquired 10,000 shares of the firm’s stock in a transaction dated Thursday, October 9th. The stock was purchased at an average cost of $11.15 per share, with a total value of $111,500.00. Following the completion of the acquisition, the chief executive officer directly owned 882,529 shares of the company’s stock, valued at approximately $9,840,198.35. This trade represents a 1.15% increase in their ownership of the stock. The acquisition was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, SVP Lawrence T. Weiss acquired 10,000 shares of the stock in a transaction that occurred on Tuesday, October 21st. The shares were bought at an average price of $11.81 per share, for a total transaction of $118,100.00. Following the transaction, the senior vice president owned 93,597 shares of the company’s stock, valued at $1,105,380.57. This trade represents a 11.96% increase in their ownership of the stock. The SEC filing for this purchase provides additional information. In the last three months, insiders acquired 20,890 shares of company stock valued at $239,532. 6.00% of the stock is owned by insiders.

Institutional Investors Weigh In On AngioDynamics

A number of large investors have recently added to or reduced their stakes in ANGO. UBS Group AG lifted its holdings in shares of AngioDynamics by 83.6% during the 3rd quarter. UBS Group AG now owns 1,102,488 shares of the medical instruments supplier’s stock valued at $12,315,000 after buying an additional 501,881 shares during the period. Millennium Management LLC increased its position in AngioDynamics by 28.1% during the third quarter. Millennium Management LLC now owns 1,793,152 shares of the medical instruments supplier’s stock valued at $20,030,000 after acquiring an additional 393,682 shares during the last quarter. Bank of America Corp DE lifted its holdings in AngioDynamics by 729.4% in the second quarter. Bank of America Corp DE now owns 286,208 shares of the medical instruments supplier’s stock valued at $2,839,000 after acquiring an additional 251,702 shares during the period. Moore Capital Management LP boosted its position in AngioDynamics by 162.5% in the third quarter. Moore Capital Management LP now owns 237,964 shares of the medical instruments supplier’s stock worth $2,658,000 after purchasing an additional 147,324 shares during the last quarter. Finally, Armistice Capital LLC grew its stake in shares of AngioDynamics by 7.1% during the 3rd quarter. Armistice Capital LLC now owns 1,636,000 shares of the medical instruments supplier’s stock valued at $18,274,000 after purchasing an additional 108,185 shares during the period. Institutional investors own 89.43% of the company’s stock.

Analysts Set New Price Targets

A number of research analysts have issued reports on the company. Wall Street Zen cut AngioDynamics from a “buy” rating to a “hold” rating in a research note on Sunday, December 21st. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of AngioDynamics in a research report on Wednesday, October 8th. Finally, Canaccord Genuity Group increased their price objective on shares of AngioDynamics from $17.00 to $18.00 and gave the company a “buy” rating in a research report on Friday, October 3rd. Three investment analysts have rated the stock with a Buy rating and one has given a Sell rating to the stock. According to MarketBeat, AngioDynamics has a consensus rating of “Moderate Buy” and an average target price of $19.33.

AngioDynamics Company Profile

AngioDynamics, Inc is a medical technology company headquartered in Latham, New York, that develops, manufactures and markets a broad range of minimally invasive medical devices. The company’s products focus on three core areas: vascular access, peripheral vascular intervention and interventional oncology. Its solutions are designed to improve procedural outcomes, reduce complications and enhance patient comfort in hospital and outpatient settings.

In the vascular access segment, AngioDynamics offers a portfolio of devices including implanted ports, peripherally inserted central catheters (PICCs), hemodialysis catheters and specialty blood management products.